Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
7
6
6
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
The CurePSP Genetics Program
Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
TSPO PET in the Evaluation of Neuroinflammation in Patients with Multiple System Atrophy
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)